{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-008300","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.833819+00:00","generated_at":"2026-06-15T16:23:21.963063+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fortress Biotech gets second 180-day Nasdaq bid-price compliance extension to Oct 30, 2023","bullets":["Nasdaq granted second 180-day grace period under Listing Rule 5810(c)(3)(A)(ii) on May 2, 2023.","Company must demonstrate closing bid above $1.00 for 10 consecutive days by October 30, 2023.","If noncompliant by deadline, Nasdaq will issue delisting notice; company may appeal to Hearings Panel.","Common stock (FBIO) and preferred stock (FBIOP) continue trading on Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-008300","json":"https://secwatch.observer/filing/0001558370-23-008300.json","markdown":"https://secwatch.observer/filing/0001558370-23-008300.md","text":"https://secwatch.observer/filing/0001558370-23-008300.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023008300/0001558370-23-008300-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023008300/fbio-20230502x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T16:23:21.963063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6847a4a946175c8895656f3a7360489dafb39378","claim":"Fortress Biotech, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(ii)).","evidence_excerpt":"May 2, 2023, in accordance with Nasdaq Listing Rule 5810(c)(3)(A)(ii), the Staff granted the Company a second 180-calendar day grace period to regain compliance with the Rule. The Company intends to closely monitor the closing bid price for its Common Stock and consider all available options to remedy the bid price deficiency. In the event the Company is not able to demonstrate compliance with the Rule by October 30, 2023, the Staff will provide written notification that the Company’s Common Stock is subject to delisting, which the Company may appeal. The Company’s appeal request would stay an","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023008300/0001558370-23-008300-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)(ii)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}